BioSpace News Archive

Galt Pharmaceuticals announced the acquisition of a specialty branded product from Fortovia Therapeutics.

- First at-home, virtually guided service to bring rapid, reliable and affordable testing into the home where the result is delivered in minutes - Abbott and eMed™ expect to deliver and administer 30 million BinaxNOW™ tests in the first quarter of 2021, with an additional 90 million in the second quarter - $25 cost for the test and service is the lowest available for at-home testing, which supports the home user to ensure a successful testing process

Today, the U.S. Food and Drug Administration issued a new emergency use authorization (EUA) for the BinaxNOW COVID-19 Ag Card Home Test which is authorized for use by patients at home with a prescription.

This Proposed Pharma Grade Version of Tauri-Gum™ is Being Developed Specifically to Target: Patients Subjected to Ongoing Chemotherapy Treatment

Today, the U.S. Food and Drug Administration granted marketing authorization—under the De Novo premarket review pathway—for an anterior cruciate ligament (ACL) implant, intended to serve as an alternative to ACL reconstruction to treat ACL tears. The device, the Bridge-Enhanced ACL Repair (BEAR) Implant, unlike traditional rec

Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced that Health Care Service Corporation (HCSC), the largest customer-owned health insurance company in the U.S., has issued a positive coverage decision that includes Home Sleep Apnea tests (HSATs) utilizing Peripheral Arterial Tonometry (PAT

AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, announced the appointment of Djordje Filipovic, PhD, as Chief Commercial Officer.

Lipidor AB announced that the Company has signed a new cooperation agreement with Aurena Laboratories AB. Over a five-year period, Lipidor will invest up to SEK 15 million in the new collaboration.

Biotechnology company launches to accelerate development of precision medicines for genetically defined neurological and immunological diseases

On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. announced that they have reached a strategic cooperation.